| __timestamp | Dynavax Technologies Corporation | Veracyte, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 17763000 | 40786000 |
| Thursday, January 1, 2015 | 22180000 | 47876000 |
| Friday, January 1, 2016 | 37257000 | 52035000 |
| Sunday, January 1, 2017 | 27367000 | 55348000 |
| Monday, January 1, 2018 | 64770000 | 65276000 |
| Tuesday, January 1, 2019 | 74986000 | 82720000 |
| Wednesday, January 1, 2020 | 79256000 | 89118000 |
| Friday, January 1, 2021 | 100156000 | 181193000 |
| Saturday, January 1, 2022 | 131408000 | 174078000 |
| Sunday, January 1, 2023 | 152946000 | 184232000 |
Data in motion
In the competitive landscape of biotechnology, understanding financial trends is crucial. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Veracyte, Inc. and Dynavax Technologies Corporation from 2014 to 2023. Over this period, Veracyte's SG&A expenses grew by approximately 350%, peaking in 2023. Meanwhile, Dynavax saw a staggering increase of over 750%, reflecting its aggressive expansion strategy. Notably, both companies experienced significant jumps in 2021, with Veracyte's expenses nearly doubling from the previous year. This trend highlights the increasing operational costs in the biotech sector, driven by innovation and market expansion. Investors and stakeholders should consider these financial dynamics when evaluating the long-term viability and strategic direction of these companies.
Operational Costs Compared: SG&A Analysis of Johnson & Johnson and Veracyte, Inc.
SG&A Efficiency Analysis: Comparing Regeneron Pharmaceuticals, Inc. and Veracyte, Inc.
Alnylam Pharmaceuticals, Inc. or Veracyte, Inc.: Who Manages SG&A Costs Better?
Sarepta Therapeutics, Inc. vs Veracyte, Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Blueprint Medicines Corporation and Dynavax Technologies Corporation
Madrigal Pharmaceuticals, Inc. and Dynavax Technologies Corporation: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Grifols, S.A. vs Dynavax Technologies Corporation Trends and Insights
SG&A Efficiency Analysis: Comparing TG Therapeutics, Inc. and Veracyte, Inc.
Amneal Pharmaceuticals, Inc. or Veracyte, Inc.: Who Manages SG&A Costs Better?
Veracyte, Inc. vs Merus N.V.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Veracyte, Inc. and ACADIA Pharmaceuticals Inc.
Selling, General, and Administrative Costs: Vericel Corporation vs Dynavax Technologies Corporation